These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 20944171

  • 1. Complete response obtained by bortezomib plus dexamethasone in a patient with relapsed multiple myeloma with multiple plasmacytomas.
    Fukushima T, Nakamura T, Miki M, Sakai T, Iwao H, Nakajima A, Sawaki T, Fujita Y, Tanaka M, Masaki Y, Hirose Y, Umehara H.
    Anticancer Res; 2010 Sep; 30(9):3791-4. PubMed ID: 20944171
    [Abstract] [Full Text] [Related]

  • 2. [Once-weekly bortezomib plus dexamethasone therapy induced complete response, reducing severe gastrointestinal adverse events for a patient with relapsed multiple myeloma - a case report].
    Fukushima T, Iwao H, Sakai T, Sato T, Nakamura T, Nakajima A, Miki M, Sawaki T, Fujita Y, Tanaka M, Masaki Y, Umehara H.
    Gan To Kagaku Ryoho; 2012 May; 39(5):805-7. PubMed ID: 22584336
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.
    Fukushima T, Nakamura T, Iwao H, Nakajima A, Miki M, Sato T, Sakai T, Sawaki T, Fujita Y, Tanaka M, Masaki Y, Nakajima H, Motoo Y, Umehara H.
    Anticancer Res; 2011 Jun; 31(6):2297-302. PubMed ID: 21737655
    [Abstract] [Full Text] [Related]

  • 4. Bortezomib in relapsed multiple myeloma complicated by extramedullary plasmacytomas.
    Hughes M, Micallef-Eynaud P.
    Clin Lab Haematol; 2006 Aug; 28(4):267-9. PubMed ID: 16898968
    [Abstract] [Full Text] [Related]

  • 5. [A clinical analysis of 25 cases of multiple myeloma complicated by extramedullary plasmacytomas].
    Zhong YP, Chen SL.
    Zhonghua Nei Ke Za Zhi; 2009 May; 48(5):396-8. PubMed ID: 19615158
    [Abstract] [Full Text] [Related]

  • 6. [Very good partial response and long time to progression by short-term bortezomib plus dexamethasone therapy for a patient with relapsed and refractory multiple myeloma-a case report].
    Fukushima T, Iwao H, Nakajima A, Miki M, Sakai T, Sawaki T, Tanaka M, Masaki Y, Hirose Y, Umehara H.
    Gan To Kagaku Ryoho; 2009 Aug; 36(8):1387-9. PubMed ID: 19692786
    [Abstract] [Full Text] [Related]

  • 7. [Effects of bortezomib at different doses in combination with dexamethasone in treatment of relapsed or refractory multiple myeloma: a comparative study].
    Bao L, Lu XJ, Zhang XH, Huang XJ.
    Zhonghua Yi Xue Za Zhi; 2008 Jul 08; 88(26):1829-31. PubMed ID: 19040018
    [Abstract] [Full Text] [Related]

  • 8. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
    Katodritou E, Terpos E, Symeonidis AS, Pouli A, Kelaidi C, Kyrtsonis MC, Kotsopoulou M, Delimpasi S, Christoforidou A, Giannakoulas N, Viniou NA, Stefanoudaki E, Hadjiaggelidou C, Christoulas D, Verrou E, Gastari V, Papadaki S, Polychronidou G, Papadopoulou A, Giannopoulou E, Kastritis E, Kouraklis A, Konstantinidou P, Anagnostopoulos A, Zervas K, Dimopoulos MA.
    Am J Hematol; 2014 Aug 08; 89(8):803-8. PubMed ID: 24757085
    [Abstract] [Full Text] [Related]

  • 9. [Loss of CD23 expression after bortezomib plus dexamethasone therapy in CCND1/IGH-positive multiple myeloma].
    Fujimi A, Hashimoto A, Kanisawa Y, Okuda T, Minami S, Doi T, Matsuno T, Ishikawa K, Uemura N.
    Rinsho Ketsueki; 2013 Feb 08; 54(2):224-8. PubMed ID: 23470832
    [Abstract] [Full Text] [Related]

  • 10. [Clinical analysis of multiple myeloma with extramedullary plasmacytomas].
    Li X, Sun WJ, Chen SL, Zhong YP, An N, Hu Y, Zhang JJ, Liu XH.
    Zhonghua Yi Xue Za Zhi; 2012 Mar 27; 92(12):838-41. PubMed ID: 22781459
    [Abstract] [Full Text] [Related]

  • 11. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
    Petrucci MT, Giraldo P, Corradini P, Teixeira A, Dimopoulos MA, Blau IW, Drach J, Angermund R, Allietta N, Broer E, Mitchell V, Bladé J.
    Br J Haematol; 2013 Mar 27; 160(5):649-59. PubMed ID: 23293914
    [Abstract] [Full Text] [Related]

  • 12. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
    Yuan ZG, Jin J, Huang XJ, Li Y, Chen WM, Liu ZG, Chen XQ, Shen ZX, Hou J.
    Chin Med J (Engl); 2011 Oct 27; 124(19):2969-74. PubMed ID: 22040537
    [Abstract] [Full Text] [Related]

  • 13. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
    Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N, Eleftherakis-Papaiakovou E, Tsionos K, Croucher P, Dimopoulos MA.
    Leukemia; 2008 Dec 27; 22(12):2247-56. PubMed ID: 18769451
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
    Berenson JR, Yang HH, Vescio RA, Nassir Y, Mapes R, Lee SP, Wilson J, Yellin O, Morrison B, Hilger J, Swift R.
    Ann Hematol; 2008 Aug 27; 87(8):623-31. PubMed ID: 18463870
    [Abstract] [Full Text] [Related]

  • 15. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, Purner M, Lee SP, Wilson J, Morrison B, Adams J, Schenkein D, Swift R.
    J Clin Oncol; 2006 Feb 20; 24(6):937-44. PubMed ID: 16418495
    [Abstract] [Full Text] [Related]

  • 16. [Efficacy of bortezomib combined dexamethasone in 24 patients with multiple myeloma].
    Li J, Zhao Y, Luo SK, Huang BH, Ding Y, Tong XZ, Wang HH, Zheng D, Su C, Peng AH.
    Ai Zheng; 2008 Apr 20; 27(4):429-34. PubMed ID: 18423132
    [Abstract] [Full Text] [Related]

  • 17. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
    Popat R, Oakervee H, Williams C, Cook M, Craddock C, Basu S, Singer C, Harding S, Foot N, Hallam S, Odeh L, Joel S, Cavenagh J.
    Br J Haematol; 2009 Mar 20; 144(6):887-94. PubMed ID: 19183191
    [Abstract] [Full Text] [Related]

  • 18. Multiple myeloma with multiple and bulky extramedullary plasmacytomas as initial presentation.
    SAWADA T, NAJIMA Y, OHASHI K, KATO I, MIYAZAWA M, NAKANO M, KOBAYASHI T, YAMASHITA T, AKIYAMA H, SAKAMAKI H.
    Rinsho Ketsueki; 2009 Nov 20; 50(11):1635-40. PubMed ID: 20009440
    [Abstract] [Full Text] [Related]

  • 19. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
    Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Redman KC, McKenney M, Warren D, Noonan K, Lunde L, Doss D, Colson K, Hideshima T, Mitsiades C, Munshi NC, Anderson KC.
    Eur J Haematol; 2012 May 20; 88(5):446-9. PubMed ID: 22300348
    [Abstract] [Full Text] [Related]

  • 20. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
    Bensinger WI, Jagannath S, Vescio R, Camacho E, Wolf J, Irwin D, Capo G, McKinley M, Potts P, Vesole DH, Mazumder A, Crowley J, Becker P, Hilger J, Durie BG.
    Br J Haematol; 2010 Feb 20; 148(4):562-8. PubMed ID: 19919652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.